An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

Namodenoson, has been also granted Orphan Drug Designation by the FDA for pancreatic cancer. The designation as an orphan drug will provide, among others, potential for market exclusivity for seven ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...

An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive ...

Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherapy through ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion ...

Among patients with unresectable, non-metastatic hepatocellular carcinoma, treatment with Lenvima (Lenvatinib) plus Keytruda (pembrolizumab) in combination with transarterial chemoembolization (TACE) ...